Search research articles
Contact Us
Filters
Showing results (81-90 of 84) with videos related to
Page
of 9
Sort By:
You have reached the last page of results.
This site can display upto 84 results.
Journal of Orthopaedic Translation
|
December 11, 2024
Three-dimensional distribution of subchondral fracture lines in osteonecrosis of the femoral head
Yan-Bin Wu, Guang-Bo Liu, Huo Li, et al.
BMC Public Health
|
March 3, 2012
Impact of genital warts on health related quality of life in men and women in mainland China: a multicenter hospital-based cross-sectional study
Ju-Fang Shi, Dian-Ju Kang, Shu-Zhen Qi, et al.
Chinese Medical Journal
|
November 30, 2020
Efficacy and safety of the long-acting fusion inhibitor albuvirtide in antiretroviral-experienced adults with human immunodeficiency virus-1: interim analysis of the randomized, controlled, phase 3, non-inferiority TALENT study
Bin Su, Cheng Yao, Qing-Xia Zhao, et al.
The Journal of Infection
|
June 6, 2022
Long-acting HIV fusion inhibitor albuvirtide combined with ritonavir-boosted lopinavir for HIV-1-infected patients after failing the first-line antiretroviral therapy: 48-week randomized, controlled, phase 3 non-inferiority TALENT study
Bin Su, Cheng Yao, Qing-Xia Zhao, et al.
Page
of 9
Search research articles
Search
Showing results (81-90 of 84) with videos related to
Sort By:
Page
of 9
You have reached the last page of results.
This site can display upto 84 results.
Journal of Orthopaedic Translation
|
December 11, 2024
Three-dimensional distribution of subchondral fracture lines in osteonecrosis of the femoral head
Yan-Bin Wu, Guang-Bo Liu, Huo Li, et al.
BMC Public Health
|
March 3, 2012
Impact of genital warts on health related quality of life in men and women in mainland China: a multicenter hospital-based cross-sectional study
Ju-Fang Shi, Dian-Ju Kang, Shu-Zhen Qi, et al.
Chinese Medical Journal
|
November 30, 2020
Efficacy and safety of the long-acting fusion inhibitor albuvirtide in antiretroviral-experienced adults with human immunodeficiency virus-1: interim analysis of the randomized, controlled, phase 3, non-inferiority TALENT study
Bin Su, Cheng Yao, Qing-Xia Zhao, et al.
The Journal of Infection
|
June 6, 2022
Long-acting HIV fusion inhibitor albuvirtide combined with ritonavir-boosted lopinavir for HIV-1-infected patients after failing the first-line antiretroviral therapy: 48-week randomized, controlled, phase 3 non-inferiority TALENT study
Bin Su, Cheng Yao, Qing-Xia Zhao, et al.
Page
of 9